Abstract 45P
Background
Compared with conventional cancer chemotherapy, tyrosine kinase inhibitors show novel patterns of radiology response, therefore using chemotherapy-based response criteria can be suboptimal. Coupling the tumor’s volume as an imaging biomarker with a stratified analysis of the therapeutic response per sites of disease may offer more insightful information in drug efficacy. We propose to compare the therapeutic response between Varlitinib plus Capecitabine (VC) and Lapatinib plus Capecitabine (LC) in analyzing the changes of tumor’s volume per tumor’s locations in patients with HER2-positive metastatic breast cancer after trastuzumab therapy.
Methods
We retrospectively analyzed data from the ASLAN001-003 study (NCT02338245). At baseline, 42 patients displayed at least one target lesion, representing a set of 88 target lesions: Lung (31%), Breast (26%), liver (23%), nodes (17%), miscellaneous (3%). Responses were evaluated at week 12 on 35 patients (14 VC; 21 LC). Between two arms, we compared responses using non-parametric tests and compared the proportion of tumor at each location using the Chi-square test. We used the R software for statistics, p < 0.05 was considered a significant difference.
Results
The distribution of tumor size at baseline was different at the different tumor locations (p < 0.001). Between the two arms the proportion of tumor at each location were not equivalent with p = 0.126 and 0.06 for breast and lung tumors respectively. The global average change from baseline was VC=-64.1% and LC=-26.59% (p = 0.13) The average change of breast tumors was significantly different in the VC (-84.2%) and the LC (-24.9%) (p < 0.001) arm. Between breast and liver tumors, the average response was significantly different (p = 0.007) in the VC arm, while not in the LC arm (p = 0.94). Also, between nodal and liver tumors with p = 0.06 in the VC and p = 0.99 in LC arm.
Conclusions
The therapeutic response differed across tumor locations, the differential response was drug-dependent. For a fair comparison, the proportion of tumor at each tumor location must be balanced between arms. The stratification of the therapeutic response can be used for assessing new therapies, helping designing cocktails or refining drug’s indications.
Clinical trial identification
ASLAN001-003 - NCT02338245.
Editorial acknowledgement
Legal entity responsible for the study
Median Technologies/Aslan Pharmaceuticals.
Funding
Has not received any funding.
Disclosure
H. Beaumont: Full / Part-time employment: Median Technologies. N. Faye: Full / Part-time employment: Median Technologies. C. Klifa: Full / Part-time employment: Median Technologies. C-Y. Hsieh: Full / Part-time employment: Aslan Pharmaceuticals. All other authors have declared no conflicts of interest.
Resources from the same session
144P - Severe hypovitaminosis D in metastatic gastric cancer patients from the Northern and Southern hemispheres: Data from the EXPAND phase III trial
Presenter: Radka Obermannova
Session: Poster display session
Resources:
Abstract
145P - Role of Glasgow prognostic score in chemo-naïve patients with advanced biliary tract cancer and good performance status
Presenter: Toshikazu Moriwaki
Session: Poster display session
Resources:
Abstract
146P - Anatomic versus non-anatomic resection for hepatocellular carcinoma: A meta-analysis of high-quality studies
Presenter: Bin Zhang
Session: Poster display session
Resources:
Abstract
147P - Clinical outcomes of proximal gastrectomy versus total gastrectomy for locally advanced proximal gastric cancer: a propensity score matching analysis
Presenter: Yingtai Chen
Session: Poster display session
Resources:
Abstract
148P - Efficacy of capecitabine and oxaliplatin versus S-1 as adjuvant chemotherapy in gastric cancer after D2 lymph node dissection according to lymph node ratio and N stage
Presenter: Seunghwan Lee
Session: Poster display session
Resources:
Abstract
150P - A Phase Ib Study of IMU-131 HER2/neu peptide vaccine plus chemotherapy in patients with HER2/neu overexpressing metastatic or advanced adenocarcinoma of the stomach or gastroesophageal junction
Presenter: Yee Chao
Session: Poster display session
Resources:
Abstract
151P - Gene expression profiling for a better understanding of gastric cancer: From the perspective of metabolic rearrangement
Presenter: Midie Xu
Session: Poster display session
Resources:
Abstract
152P - Long-term outcomes of three-dimensional conformal radiotherapy-based and intensity-modulated radiotherapy-based concurrent chemoradiotherapy in patients with thoracic esophageal squamous cell carcinoma
Presenter: Chia-Lun Chang
Session: Poster display session
Resources:
Abstract
153P - Exosomal LINC00174 facilitates epithelial-mesenchymal transition in residual hepatocellular carcinoma after insufficient radiofrequency ablation by regulating c-JUN/MYCBP/c-Myc axis
Presenter: Dening Ma
Session: Poster display session
Resources:
Abstract
154P - Genetic characteristics of participants in the Australian Pancreatic Screening Study
Presenter: Krithika Murali
Session: Poster display session
Resources:
Abstract